Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
Lenovo Group Limited (LNVGY) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call November 14, 2024 9:00 PM ET. Company Participants. Jenny Lai - Vice President, Investor Relations Yuanqing Yang - Chairma ...